Signatera in High-Risk Breast Cancer
Signatera is a personalized, tumor-informed assay with the power to give you earlier, clearer insight into your patient's disease. By detecting and quantifying ctDNA, Signatera can optimize your ability to assess risk, predict recurrence, and monitor treatment response in those most at risk for progression.
Signatera is a personalized, tumor-informed assay with the power to give you earlier, clearer insight into your patient's disease. By detecting and quantifying ctDNA, Signatera can optimize your ability to assess risk, predict recurrence, and monitor treatment response in those most at risk for progression.
Unparalleled Insight in High-Risk Breast Cancer
Signatera can detect recurrence up to 2 years earlier than traditional imaging.1
Signatera predicts breast cancer recurrence earlier and with greater accuracy than traditional tools by using a highly-personalized molecular residual disease assay.1
Signatera on Radio
Listen to Natera Leadership discuss how Signatera can help breast cancer patients on Into Tomorrow with Dave Graveline
Signatera on Radio
Listen to a recent story from NPR about how Signatera can be used in different tumor types
Is Signatera right for your patients?
We’re here to help you find out
References
1Coombes C, Page K, Salari R, et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clinical Cancer Research. 2019;25(14):4255-4263.